Coccidioidomycosis and other endemic mycoses in Mexico.
The endemic mycoses traditionally include coccidioidomycosis, histoplasmosis, blastomycosis and paracoccidioidomycosis. Although sporotrichosis and chromomycosis are technically not included among the endemic mycoses, they are frequently diagnosed in Mexico. Most systemic endemic mycoses are a consequence of inhaling the fungi, while subcutaneous mycoses are acquired through the inoculation of vegetable matter or soil containing the organism. Coccidioidomycosis is caused by Coccidioides spp., a dimorphic pathogenic fungus. Approximately 60% of exposures result in asymptomatic infection; in the rest there are protean manifestations that range from a benign syndrome also known as "Valley Fever" to progressive pulmonary or extrapulmonary disease. Histoplasmosis, caused by the dimorphic fungus Histoplasma capsulatum, is endemic to the Americas. Pulmonary histoplasmosis manifestations are protean, ranging from a brief period of malaise to a severe, prolonged illness. The spectrum of illness in disseminated histoplasmosis ranges from a chronic, intermittent course to an acute and rapidly fatal infection. Paracoccidioidomycosis is a chronic, granulomatous systemic disease caused by Paracoccidioides brasiliensis that characteristically produces a primary pulmonary infection, often asymptomatic, and then disseminates to form ulcerative granulomata of the oral, nasal and occasionally the gastrointestinal mucosa. Sporotrichosis, caused by Sporothrix schenckii, has diverse clinical manifestations; the most frequent is the lymphocutaneous form. Generally, infection results from inoculation of the fungus through thorns, splinters, scratches and small traumas. Chromomycosis (Chromoblastomycosis) is a slowly progressive cutaneous and subcutaneous mycosis attributed to various saprophyte Hypomycetes fungi. The primary lesion is also thought to develop as a result of percutaneous traumatic inoculation.
Laniado-Laborín
Rafael
R
Facultad de Medicina-Tijuana, Universidad Autónoma de Baja California, México. rafaellaniado@gmail.com
D000935:Antifungal Agents / Q000627:therapeutic use; D002862:Chromoblastomycosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery; D003047:Coccidioidomycosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology* / Q000601:surgery; D003131:Combined Modality Therapy; D003452:Cryosurgery; D003646:Debridement; D003881:Dermatomycoses / Q000453:epidemiology; D019353:Endemic Diseases; D006660:Histoplasmosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D019570:Inhalation Exposure; D008800:Mexico / Q000453:epidemiology; D009181:Mycoses / Q000453:epidemiology*; D009894:Opportunistic Infections / Q000453:epidemiology / Q000382:microbiology; D010229:Paracoccidioidomycosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D013174:Sporotrichosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D014946:Wound Infection / Q000382:microbiology
D000935:Antifungal Agents